Virtus ETF Advisers LLC Purchases 1,565 Shares of CytomX Therapeutics Inc (CTMX)

Virtus ETF Advisers LLC raised its stake in shares of CytomX Therapeutics Inc (NASDAQ:CTMX) by 8.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 20,415 shares of the biotechnology company’s stock after buying an additional 1,565 shares during the quarter. Virtus ETF Advisers LLC’s holdings in CytomX Therapeutics were worth $308,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. FMR LLC grew its position in shares of CytomX Therapeutics by 15.4% during the 3rd quarter. FMR LLC now owns 6,744,553 shares of the biotechnology company’s stock worth $124,774,000 after buying an additional 900,927 shares during the period. BlackRock Inc. grew its position in shares of CytomX Therapeutics by 19.9% during the 3rd quarter. BlackRock Inc. now owns 3,868,566 shares of the biotechnology company’s stock worth $71,570,000 after buying an additional 642,165 shares during the period. Perceptive Advisors LLC grew its position in shares of CytomX Therapeutics by 38.5% during the 3rd quarter. Perceptive Advisors LLC now owns 2,661,715 shares of the biotechnology company’s stock worth $49,242,000 after buying an additional 740,000 shares during the period. Vanguard Group Inc grew its position in shares of CytomX Therapeutics by 18.3% during the 3rd quarter. Vanguard Group Inc now owns 2,504,987 shares of the biotechnology company’s stock worth $46,343,000 after buying an additional 387,722 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of CytomX Therapeutics by 18.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,504,987 shares of the biotechnology company’s stock worth $46,343,000 after buying an additional 387,722 shares during the period. Institutional investors own 83.93% of the company’s stock.

Several research firms have recently issued reports on CTMX. BidaskClub upgraded CytomX Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 11th. HC Wainwright set a $32.00 target price on CytomX Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, October 24th. Goldman Sachs Group upgraded CytomX Therapeutics from a “neutral” rating to a “buy” rating in a research report on Thursday, December 13th. ValuEngine lowered CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Finally, restated a “hold” rating on shares of CytomX Therapeutics in a research report on Tuesday, November 6th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $30.41.

Shares of CTMX traded down $0.07 on Wednesday, hitting $19.00. The company’s stock had a trading volume of 34,882 shares, compared to its average volume of 271,048. CytomX Therapeutics Inc has a fifty-two week low of $12.51 and a fifty-two week high of $35.00. The firm has a market capitalization of $852.88 million, a PE ratio of -16.38 and a beta of 0.91.

In related news, CFO Debanjan Ray sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 12th. The stock was sold at an average price of $15.00, for a total value of $45,000.00. Following the completion of the transaction, the chief financial officer now directly owns 8,928 shares in the company, valued at approximately $133,920. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.50% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: This article was posted by Markets Daily and is the property of of Markets Daily. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.themarketsdaily.com/2019/02/13/virtus-etf-advisers-llc-purchases-1565-shares-of-cytomx-therapeutics-inc-ctmx.html.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

See Also: What is the NASDAQ?

Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics Inc (NASDAQ:CTMX).

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply